268 related articles for article (PubMed ID: 31406254)
1. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
[TBL] [Abstract][Full Text] [Related]
2. A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
Machida Y; Nakagawa M; Matsunaga H; Yamaguchi M; Ogawara Y; Shima Y; Yamagata K; Katsumoto T; Hattori A; Itoh M; Seki T; Nishiya Y; Nakamura K; Suzuki K; Imaoka T; Baba D; Suzuki M; Sampetrean O; Saya H; Ichimura K; Kitabayashi I
Mol Cancer Ther; 2020 Feb; 19(2):375-383. PubMed ID: 31727689
[TBL] [Abstract][Full Text] [Related]
3. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
[TBL] [Abstract][Full Text] [Related]
5. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
[TBL] [Abstract][Full Text] [Related]
7. Targeting isocitrate dehydrogenase (IDH) in cancer.
Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
[TBL] [Abstract][Full Text] [Related]
8. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors.
Salamanca-Cardona L; Shah H; Poot AJ; Correa FM; Di Gialleonardo V; Lui H; Miloushev VZ; Granlund KL; Tee SS; Cross JR; Thompson CB; Keshari KR
Cell Metab; 2017 Dec; 26(6):830-841.e3. PubMed ID: 29056515
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of IDH mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract][Full Text] [Related]
11. Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth.
Li L; Hu X; Eid JE; Rosenberg AE; Wilky BA; Ban Y; Sun X; Galoian K; DeSalvo J; Yue J; Chen XS; Blonska M; Trent JC
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935911
[TBL] [Abstract][Full Text] [Related]
12. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
13. Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.
Jin Y; Elalaf H; Watanabe M; Tamaki S; Hineno S; Matsunaga K; Woltjen K; Kobayashi Y; Nagata S; Ikeya M; Kato T; Okamoto T; Matsuda S; Toguchida J
PLoS One; 2015; 10(7):e0131998. PubMed ID: 26161668
[TBL] [Abstract][Full Text] [Related]
14. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
[TBL] [Abstract][Full Text] [Related]
16. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.
Pusch S; Krausert S; Fischer V; Balss J; Ott M; Schrimpf D; Capper D; Sahm F; Eisel J; Beck AC; Jugold M; Eichwald V; Kaulfuss S; Panknin O; Rehwinkel H; Zimmermann K; Hillig RC; Guenther J; Toschi L; Neuhaus R; Haegebart A; Hess-Stumpp H; Bauser M; Wick W; Unterberg A; Herold-Mende C; Platten M; von Deimling A
Acta Neuropathol; 2017 Apr; 133(4):629-644. PubMed ID: 28124097
[TBL] [Abstract][Full Text] [Related]
17. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Johannessen TA; Mukherjee J; Viswanath P; Ohba S; Ronen SM; Bjerkvig R; Pieper RO
Mol Cancer Res; 2016 Oct; 14(10):976-983. PubMed ID: 27430238
[TBL] [Abstract][Full Text] [Related]
18. I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo.
Jia P; Wu Y; Du H; Yang L; Zhang Z; Ma T; Li S; Yuan S; Lu L; Zha X
Eur J Pharm Sci; 2019 Dec; 140():105072. PubMed ID: 31518680
[TBL] [Abstract][Full Text] [Related]
19. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Rohle D; Popovici-Muller J; Palaskas N; Turcan S; Grommes C; Campos C; Tsoi J; Clark O; Oldrini B; Komisopoulou E; Kunii K; Pedraza A; Schalm S; Silverman L; Miller A; Wang F; Yang H; Chen Y; Kernytsky A; Rosenblum MK; Liu W; Biller SA; Su SM; Brennan CW; Chan TA; Graeber TG; Yen KE; Mellinghoff IK
Science; 2013 May; 340(6132):626-30. PubMed ID: 23558169
[TBL] [Abstract][Full Text] [Related]
20. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]